Shared Mechanisms between Cardiovascular Disease and NAFLD.

IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Seminars in liver disease Pub Date : 2022-11-01 DOI:10.1055/a-1930-6658
Daniel Q Huang, Michael Downes, Ronald M Evans, Joseph L Witztum, Christopher K Glass, Rohit Loomba
{"title":"Shared Mechanisms between Cardiovascular Disease and NAFLD.","authors":"Daniel Q Huang,&nbsp;Michael Downes,&nbsp;Ronald M Evans,&nbsp;Joseph L Witztum,&nbsp;Christopher K Glass,&nbsp;Rohit Loomba","doi":"10.1055/a-1930-6658","DOIUrl":null,"url":null,"abstract":"<p><p>The burden of nonalcoholic fatty liver disease (NAFLD) is rising globally. Cardiovascular disease is the leading cause of death in patients with NAFLD. Nearly half of individuals with NAFLD have coronary heart disease, and more than a third have carotid artery atherosclerosis. Individuals with NAFLD are at a substantially higher risk of fatal and nonfatal cardiovascular events. NAFLD and cardiovascular disease share multiple common disease mechanisms, such as systemic inflammation, insulin resistance, genetic risk variants, and gut microbial dysbiosis. In this review, we discuss the epidemiology of cardiovascular disease in NAFLD, and highlight common risk factors. In addition, we examine recent advances evaluating the shared disease mechanisms between NAFLD and cardiovascular disease. In conclusion, multidisciplinary collaborations are required to further our understanding of the complex relationship between NAFLD and cardiovascular disease and potentially identify therapeutic targets.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828940/pdf/nihms-1845665.pdf","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in liver disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-1930-6658","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 11

Abstract

The burden of nonalcoholic fatty liver disease (NAFLD) is rising globally. Cardiovascular disease is the leading cause of death in patients with NAFLD. Nearly half of individuals with NAFLD have coronary heart disease, and more than a third have carotid artery atherosclerosis. Individuals with NAFLD are at a substantially higher risk of fatal and nonfatal cardiovascular events. NAFLD and cardiovascular disease share multiple common disease mechanisms, such as systemic inflammation, insulin resistance, genetic risk variants, and gut microbial dysbiosis. In this review, we discuss the epidemiology of cardiovascular disease in NAFLD, and highlight common risk factors. In addition, we examine recent advances evaluating the shared disease mechanisms between NAFLD and cardiovascular disease. In conclusion, multidisciplinary collaborations are required to further our understanding of the complex relationship between NAFLD and cardiovascular disease and potentially identify therapeutic targets.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心血管疾病和NAFLD的共同机制。
非酒精性脂肪性肝病(NAFLD)的负担正在全球范围内上升。心血管疾病是NAFLD患者死亡的主要原因。近一半的NAFLD患者患有冠心病,超过三分之一的患者患有颈动脉粥样硬化。NAFLD患者发生致死性和非致死性心血管事件的风险更高。NAFLD和心血管疾病有多种共同的发病机制,如全身性炎症、胰岛素抵抗、遗传风险变异和肠道微生物生态失调。在这篇综述中,我们讨论了NAFLD中心血管疾病的流行病学,并强调了常见的危险因素。此外,我们研究了评估NAFLD和心血管疾病之间共同疾病机制的最新进展。总之,需要多学科合作来进一步了解NAFLD与心血管疾病之间的复杂关系,并潜在地确定治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in liver disease
Seminars in liver disease 医学-胃肠肝病学
CiteScore
8.20
自引率
2.40%
发文量
38
期刊介绍: Seminars in Liver Disease is a quarterly review journal that publishes issues related to the specialties of hepatology and gastroenterology. As the premiere review journal in the field, Seminars in Liver Disease provides in-depth coverage with articles and issues focusing on topics such as cirrhosis, transplantation, vascular and coagulation disorders, cytokines, hepatitis B & C, Nonalcoholic Steatosis Syndromes (NASH), pediatric liver diseases, hepatic stem cells, porphyrias as well as a myriad of other diseases related to the liver. Attention is also given to the latest developments in drug therapy along with treatment and current management techniques. Seminars in Liver Disease publishes commissioned reviews. Unsolicited reviews of an exceptional nature or original articles presenting remarkable results will be considered, but case reports will not be published.
期刊最新文献
Mitochondria and Alcohol-Associated Liver Disease: Pathogenic Role and Target for Therapy. Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury. Role of the Gut Microbiome in Metabolic dysfunction-Associated Steatotic Liver Disease. Patient Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease. Management of Portal vein Thrombosis in Cirrhosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1